Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400926 · ClinicalTrials.gov registry record
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
A clinical trial of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT07400926: Recruiting study of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), sponsored by Glaukos Corporation.
NCT07400926 is a study of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH) that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 30 participants, below the 62-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07400926, a study of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
Primary Outcome
Proportion of subjects for which Investigator was able to successfully follow the Instructions For Use/Prescribing Information and correctly administer the model G2-TRIO travoprost intracameral implant 75mcg with the updated inserter
Conditions Studied
Interventions
- COMBINATION_PRODUCT Travoprost
Study Locations (1)
Wisconsin
- Glaukos Investigative Site - Kenosha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2026-07 |
What NCT07400926 shows while recruiting
NCT07400926 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 62-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which Travoprost is the first listed.
NCT07400926 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07400926 about?
NCT07400926 is a clinical study titled "Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg". Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
What is the current status of trial NCT07400926?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-12-17. Estimated completion is 2026-07.
What conditions does trial NCT07400926 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH).
What interventions are being tested in trial NCT07400926?
The interventions under investigation include: Travoprost (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07400926?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400926 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI